The FDA removed semaglutide from its shortage list, affecting Hims & Hers' sales strategy. Hims & Hers' revenue grew by 69% in 2024, with GLP-1 drugs representing about 15% of sales. The move: Hims & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback